Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Monday, December 19, 2016

Lack of natalizumab concentration increase before PML argues against extending dosing interval


                                                                  
  

Click here to receive MS news via e-mail


Publish date: December 14, 2016
By: Jeff Evans  Frontline Medical News


Key clinical point: Extending the dosing interval of natalizumab to a maximum of 8 weeks in order to lower its serum concentration may not do anything to reduce the risk of PML.

Major finding: A total of 10 control patients had a mean natalizumab serum concentration of 23.8 mcg/mL, which was in the same range as the 18.9 mcg/mL level observed in 5 patients before a diagnosis of PML.

Data source: A comparison of 5 patients with PML and 10 age- and sex-matched controls from a prospective cohort of 219 patients with relapsing-remitting MS who were treated with natalizumab at one center.

Disclosures: The study received support from the Brain Foundation Netherlands. Five of the authors reported financial ties to various pharmaceutical companies that market MS drugs, including Biogen, which markets natalizumab.


Read complete article here





MS Views and News
Providing educational information, resources and services for those affected by MS
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis





No comments: